A couple years ago we unveiled a new startup called Nimbus Discovery LLC which was experimenting with a new model that combined three key elements: Schrodinger's cutting edge in silico drug screening ...

Today Gilead announced the acquisition of Nimbus’ lead program targeting NASH and related metabolic disorders for $400M upfront and up to another $800M in development and regulatory milestones (here).

Jason Cipriani is based out of beautiful Colorado and has been covering mobile technology news and reviewing the latest gadgets for the last six years. His work can also be found on sister site CNET ...